Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis.
Mycobacterium tuberculosis is estimated to infect 80 to 100 million people annually, the majority of whom do not develop clinical tuberculosis (TB) but instead maintain the infection in a latent state. These individuals generally become positive in response to a tuberculin skin test and may develop...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2006
|
| _version_ | 1826279727629860864 |
|---|---|
| author | Demissie, A Leyten, E Abebe, M Wassie, L Aseffa, A Abate, G Fletcher, H Owiafe, P Hill, P Brookes, R Rook, G Zumla, A Arend, S Klein, M Ottenhoff, T Andersen, P Doherty, T |
| author_facet | Demissie, A Leyten, E Abebe, M Wassie, L Aseffa, A Abate, G Fletcher, H Owiafe, P Hill, P Brookes, R Rook, G Zumla, A Arend, S Klein, M Ottenhoff, T Andersen, P Doherty, T |
| author_sort | Demissie, A |
| collection | OXFORD |
| description | Mycobacterium tuberculosis is estimated to infect 80 to 100 million people annually, the majority of whom do not develop clinical tuberculosis (TB) but instead maintain the infection in a latent state. These individuals generally become positive in response to a tuberculin skin test and may develop clinical TB at a later date, particularly if their immune systems are compromised. Latently infected individuals are interesting for two reasons. First, they are an important reservoir of M. tuberculosis, which needs to be considered for TB control. Second, if detected prior to recrudescence of the disease, they represent a human population that is making a protective immune response to M. tuberculosis, which is very important for defining correlates of protective immunity. In this study, we show that while responsiveness to early secretory antigenic target 6 is a good marker for M. tuberculosis infection, a strong response to the 16-kDa Rv2031c antigen (HspX or alpha-crystallin) is largely restricted to latently infected individuals, offering the possibility of differential immunodiagnosis of, or therapeutic vaccination against, TB. |
| first_indexed | 2024-03-07T00:03:06Z |
| format | Journal article |
| id | oxford-uuid:76a57420-1cfd-4f83-8c44-fa154565997a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:03:06Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:76a57420-1cfd-4f83-8c44-fa154565997a2022-03-26T20:17:38ZRecognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:76a57420-1cfd-4f83-8c44-fa154565997aEnglishSymplectic Elements at Oxford2006Demissie, ALeyten, EAbebe, MWassie, LAseffa, AAbate, GFletcher, HOwiafe, PHill, PBrookes, RRook, GZumla, AArend, SKlein, MOttenhoff, TAndersen, PDoherty, TMycobacterium tuberculosis is estimated to infect 80 to 100 million people annually, the majority of whom do not develop clinical tuberculosis (TB) but instead maintain the infection in a latent state. These individuals generally become positive in response to a tuberculin skin test and may develop clinical TB at a later date, particularly if their immune systems are compromised. Latently infected individuals are interesting for two reasons. First, they are an important reservoir of M. tuberculosis, which needs to be considered for TB control. Second, if detected prior to recrudescence of the disease, they represent a human population that is making a protective immune response to M. tuberculosis, which is very important for defining correlates of protective immunity. In this study, we show that while responsiveness to early secretory antigenic target 6 is a good marker for M. tuberculosis infection, a strong response to the 16-kDa Rv2031c antigen (HspX or alpha-crystallin) is largely restricted to latently infected individuals, offering the possibility of differential immunodiagnosis of, or therapeutic vaccination against, TB. |
| spellingShingle | Demissie, A Leyten, E Abebe, M Wassie, L Aseffa, A Abate, G Fletcher, H Owiafe, P Hill, P Brookes, R Rook, G Zumla, A Arend, S Klein, M Ottenhoff, T Andersen, P Doherty, T Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. |
| title | Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. |
| title_full | Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. |
| title_fullStr | Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. |
| title_full_unstemmed | Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. |
| title_short | Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. |
| title_sort | recognition of stage specific mycobacterial antigens differentiates between acute and latent infections with mycobacterium tuberculosis |
| work_keys_str_mv | AT demissiea recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT leytene recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT abebem recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT wassiel recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT aseffaa recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT abateg recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT fletcherh recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT owiafep recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT hillp recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT brookesr recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT rookg recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT zumlaa recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT arends recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT kleinm recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT ottenhofft recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT andersenp recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis AT dohertyt recognitionofstagespecificmycobacterialantigensdifferentiatesbetweenacuteandlatentinfectionswithmycobacteriumtuberculosis |